Exagen stock gained 1.34 percent on October 7

Published on 10/08/2026 at 03:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

At USD 8.30, Exagen stock finished October 7, 2026, 32.1 percent below its 52-week high. Q2 revenue beat estimates at USD 19.94 million.

XGN, US30068X1037, Illustration mit AI erstellt.

Exagen stock (ISIN US30068X1037) was last at USD 8.30 on Nasdaq on October 7, 2026, at 4:00 p.m. ET, up 1.34 percent from USD 8.19. The price report puts the medical diagnostics company 32.1 percent below its 52-week high of USD 12.23, while its 52-week low is USD 2.59.

Revenue beat estimates in Q2

Exagen's latest reported quarter was Q2 2026, which ended June 30. According to MarketBeat on September 21, 2026, the company reported revenue of USD 19.94 million against a consensus estimate of USD 17.80 million. Adjusted loss per share was USD 0.13, compared with the expected loss of USD 0.19.

The quarterly revenue figure represented a 16 percent year-over-year increase. Benzinga reported on September 17, 2026, that Exagen narrowed its adjusted EBITDA loss to USD 0.1 million from USD 1.7 million in Q2 2025. The company also raised full-year 2026 revenue guidance from USD 70 million to USD 73 million to a range of USD 72 million to USD 75 million.

Analysts see measured upside

According to MarketBeat on September 21, 2026, nine analysts covering Exagen had a Moderate Buy consensus. Seven analysts rated the stock Buy, one rated it Strong Buy and one rated it Sell. The average 12-month price target was USD 9.6250, which stands 16.0 percent above USD 8.30.

The operating figures point to improving scale, but profitability remains the key checkpoint. Benzinga said Exagen's trailing 12-month average selling price reached USD 446 in Q2 2026, up USD 18 from the prior year, while management identified adjusted EBITDA breakeven at annual revenue of USD 80 million.

November results set the next test

MarketBeat lists November 3, 2026, as the date for Exagen's Q3 2026 earnings report. The estimate shown for that quarter is a consensus loss of USD 0.19 per share and expected revenue of USD 18.34 million.

Exagen stock stays below its yearly high

Exagen stock was last at USD 8.30 on Nasdaq on October 7, 2026, with a market capitalization of USD 200.5 million and volume of 234,913 shares. The next valuation test is whether the company can convert its higher revenue base into adjusted EBITDA breakeven.